Targeting DNGR-1 (CLEC9A) With Antibody/Muc1 Peptide Conjugates as a Vaccine for Carcinomas

European Journal of Immunology - United Kingdom
doi 10.1002/eji.201344076
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Synthesis of Immunoadjuvant Conjugates With HIV-Derived Peptide Inducing Peptide-Specific Antibody.

Chemical and Pharmaceutical Bulletin
MedicineDrug DiscoveryChemistry
1994English

A Phase 1 Dose Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA With Costimulatory Molecules

Clinical Cancer Research
Cancer ResearchOncology
2019English

Phase 1 Trials of Anti-Enpp3 Antibody Drug Conjugates in Advanced Refractory Renal Cell Carcinomas

Clinical Cancer Research
Cancer ResearchOncology
2018English

Antibody-Dm1 Conjugates as Cancer Therapeutics

Cancer Letters
Cancer ResearchOncology
2011English

Antibody Response to Melanoma Helper-Peptide Vaccine Correlates With Survival

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2013English

Peptide–drug Conjugates as Effective Prodrug Strategies for Targeted Delivery

Advanced Drug Delivery Reviews
Pharmaceutical Science
2017English

Design of a MUC1-based Cancer Vaccine

Biochemical Society Transactions
Biochemistry
2005English

Antibody-Drug Conjugates With Pyrrole-Based KSP Inhibitors as the Payload Class

Angewandte Chemie - International Edition
CatalysisChemistry
2018English

Multiepitope CD8+ T Cell Response to a NY-ESO-1 Peptide Vaccine Results in Imprecise Tumor Targeting

Journal of Clinical Investigation
Medicine
2002English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy